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Abstract 
Objective: Distinguishing early dilated cardiomyopathy (DCM) from physiological left 
ventricular (LV) dilatation with LV ejection fraction <55% in athletes (‘grey-zone’) is 
challenging. We evaluated the role of a cascade of investigations to differentiate these two 
entities. 
Methods:  Thirty-five asymptomatic active males with DCM, 25 male athletes in the ‘grey-
zone’ and 24 male athletes with normal LV ejection fraction underwent  NT-proBNP 
measurement, ECG and exercise echocardiography. ‘Grey-zone’ athletes and DCM patients 
underwent cardiovascular magnetic resonance (CMR) and Holter monitoring.  
Results: Larger LV cavity dimensions and lower LV ejection fraction were the only 
differences between ‘grey-zone’ and control athletes. None of the ‘grey-zone’ athletes had  
abnormal NT-proBNP, increased ectopic burden/complex arrhythmias or pathological late 
gadolinium enhancement on CMR. These features were also absent in 71%, 71% and 50%  
DCM patients respectively.  95% ‘grey-zone’ athletes and 60% DCM patients had  normal 
ECG.  During exercise echocardiography, 96%  ‘grey-zone’ athletes increased LV ejection 
fraction by >11% from baseline to peak exercise compared with 23% DCM patients 
(p<0.0001). Peak LV ejection fraction was >63% in 92% ‘grey-zone’ athletes compared with 
17% DCM patients (p<0.0001). Failure to increase LV ejection fraction >11% from baseline 
to peak exercise or achieve a peak LV ejection fraction >63% had sensitivity of 77% and 
83% respectively and specificity of 96% and 92% respectively for predicting DCM.  
Conclusion: Comprehensive assessment using a cascade of routine investigations revealed 
that exercise stress echocardiography has the greatest discriminatory value in differentiating 
between ‘grey-zone’ athletes and asymptomatic DCM patients. Our findings require 
validation in larger studies. 
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Key Questions 
What is known about this subject? 
Dilated cardiomyopathy (DCM) is a recognized cause of sudden death in young athletes. It is 
also known that around 11% of healthy endurance athletes develop physiological left 
ventricular dilatation with a low/borderline left ventricular ejection fraction that may simulate 
dilated cardiomyopathy. Thus a distinct ‘grey-zone’ exists between physiological remodelling 
and dilated cardiomyopathy where erroneous misinterpretation has potentially serious 
consequences.  
 
What does this study add? 
We have demonstrated that failure to increase LV ejection fraction >11% from baseline to 
peak exercise and inability to augment the LV ejection fraction >63% at peak exercise during 
exercise stress echocardiography is suggestive of DCM with high sensitivity of around 80% 
and specificity >90%. Additionally, we used a composite of routine investigations to derive 
an algorithm to help clinicians to differentiate between athletes with a physiological increase 
in LV size and borderline or low baseline LV ejection fraction (‘grey-zone’) and DCM. The 
algorithm has a sensitivity of 94.1%, specificity of 83.3%, positive predictive value of 88.9% 
and negative predictive value of 90.9% in predicting DCM.  
How might this impact clinical practice? 
An erroneous diagnosis of DCM in an athlete with a physiologically increased LV size and 
borderline or low resting LV ejection fraction may lead to unnecessary disqualification from 
sport. Conversely, an erroneous diagnosis of athlete’s heart in an individual with 
morphologically mild DCM deprives the individual of prognostic medications and provides 
false reassurance which may culminate in progressive deterioration of LV function and an 
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exercise related sudden death.  Our findings and proposed algorithm will aid cardiologists 
and sports physicians when assessing active individuals with LV dilatation and LV ejection 
fraction<55% (‘grey-zone’). Although our results are promising, the numbers are relatively 
small and require validation in a larger cohort. 
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Abbreviations:  
 
CPET  Cardiopulmonary exercise test 
CMR  Cardiovascular Magnetic Resonance 
DCM  Dilated cardiomyopathy 
ECG  Electrocardiogram 
LV  Left ventricular 
NT-proBNP  N-terminal pro-brain natriuretic peptide 
pV02  Peak oxygen consumption 
TDI  Tissue Doppler Imaging 
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INTRODUCTION 
Dilated cardiomyopathy (DCM) is a rare but recognised cause of sudden cardiac death in 
athletes1. A small proportion of endurance athletes show enlarged left ventricular (LV) 
cavities with borderline/low LV ejection fraction2 which overlaps with the phenotypic 
expression of morphologically mild DCM.  Differentiation between these entities is an 
important focus of the sports cardiology and imaging societies. Expert opinion suggests that 
comprehensive assessment including the electrocardiogram (ECG), advanced imaging such 
exercise stress echocardiography, 2-D strain imaging and the presence of late enhancement 
on cardiovascular magnetic resonance imaging (CMR) is necessary to differentiate these 2 
entities3,4; however data regarding utility of such investigations  in this context is limited. We 
sought to evaluate the role of conventional investigations to differentiate between 
physiological adaptation in healthy athletes with LV dilatation and LVEF<55% (‘grey-zone’) 
and active asymptomatic individuals with DCM. 
 
METHODS 
The data, analytical methods, and study materials will not be made available to other 
researchers for the purpose of reproducing the results or replicating the procedure. 
Researchers interested in the data, methods, or analysis can contact the corresponding author 
for more information. Patients and public were not involved in the design, conduct, reporting 
or dissemination plans of our research. 
Study subjects: 
Patients with Dilated Cardiomyopathy 
Asymptomatic male patients with non-ischaemic DCM were recruited from two tertiary 
cardiomyopathy centres in London.  Dilated cardiomyopathy was defined as systolic 
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impairment in association with LV enlargement (either LV end-diastolic dimension >58mm 
or  LV end diastolic volume of >150mls,equating to 2 standard deviations above the mean, as 
per the American Society of Echocardiography )5.Left ventricular impairment was defined as 
LV ejection fraction <55%. Exclusion criteria included ischaemic heart disease, hypertension, 
valvular disease, LV ejection fraction<35% and poor echocardiographic windows. In 
individuals who exercised more than 5 hours of exercise per week, DCM was confirmed by 
the presence of DCM in a first degree relative, remodelled severe LV systolic dysfunction or 
late enhancement on CMR. Thirty-five individuals who fulfilled these criteria agreed to 
participate in the study.   
 
Healthy athletes with LV dilatation and LVEF<55% (‘grey-zone’) 
In the United Kingdom, the charity Cardiac Risk in the Young (CRY) subsidises pre-
participation cardiovascular evaluations for elite professional and national sporting 
organisations. Over the period 2015-2017, 8006 athletes were evaluated by CRY. 
Additionally, the sports cardiology unit at St George’s Hospital is a quaternary referral centre 
for athletes from centres throughout the country.   Twenty-five asymptomatic athletes with 
phenotypic features resembling DCM were recruited from these sources.   The ‘grey-zone’ 
was defined as an athlete with LV enlargement and borderline ejection fraction (<55%) who 
exercised for ≥8 hours per week. Athletes with a family history of DCM were excluded. 
Athlete controls 
A control cohort of 24 healthy asymptomatic male athletes with normal LV geometry 
matched to athletes with an increased LV cavity and LV ejection fraction <55% for age and 
sporting discipline were recruited through the CRY screening programme. 
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Study protocol 
Participants underwent health questionnaire, NT-proBNP, 12-lead ECG, baseline and 
exercise echocardiogram and cardiopulmonary exercise testing (CPET). Beta-blockade-was 
held for 48 hours prior to exercise testing.  ‘Grey-zone’ athletes and DCM patients also 
underwent a CMR and 24 hour Holter monitor.  
Health Questionnaire: 
The health questionnaire contained questions regarding cardiovascular symptoms, family 
history and exercise activity. 
NT-proBNP 
Blood samples for NT-proBNP were obtained from participants during resting conditions. 
Analysis was performed within 2 hours of extraction at room temperature using a Cobas 8000 
E602 Module Immunochemistry Analyser (Roche Diagnostics, Basel, Switzerland). 
Electrocardiography 
12-lead ECG was performed in the supine position in a quiet room using a  GE Marquette 
Hellige (Milwaukee, WI) ECG machine with a paper speed of 25mm/s as described6. 
Electrocardiograms were interpreted in accordance with  international guidelines7. 
Twenty-four hour Holter  
Twenty-four hour ambulatory ECG monitoring was performed using Life Card CF Holters 
(Spacelabs Healthcare).  A high ventricular ectopic (VE)  burden >500 beats/24 hours8 or the 
presence of non-sustained ventricular tachycardia (NSVT)  were considered abnormal. The 
presence of NSVT was defined as ≥3 consecutive beats of >120ms9.  
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Echocardiography 
Two-dimensional transthoracic echocardiography was performed by 2 board accredited 
sonographers using a commercially available, portable ultrasound system (Vivid E9, GE 
Healthcare, Milwaukee, Wisconsin) with a 1.5 – 3.6 MHz phased array transducer. 
Conventional views were obtained and measurements made as per the American Society of 
Echocardiography5. Pulsed-wave Doppler recordings were obtained to assess transmitral 
Doppler and  Tissue Doppler Imaging (TDI) was acquired at the lateral and septal mitral 
annulus10. M-mode echocardiography was used to assess the tricuspid annular plane systolic 
excursion (TAPSE). 
Speckle Tracking Imaging 
Speckle tracking imaging was performed using a designated speckle tracking package (GE 
EchoPAC Clinical Workstation Software (Pollards Wood, UK)) to obtain global LV 
longitudinal strain (GLS) in the 2-,3-,4- chamber views then averaged accordingly. A normal 
GLS value was <-17%5. 
Stress echocardiography  
Exercise echocardiography was conducted on a semi-recumbent cycle ergometer (Lode 
Angio with Echo Cardiac Stress Table, Groningen, Netherlands) according to a ramp protocol 
of 20 W/min to volitional exhaustion. Standard apical, parasternal short and long-axis images 
and transmitral Doppler and TDI of the lateral wall were acquired at baseline and peak 
exercise. Left ventricular volumes and ejection fraction were calculated using the Simpson’s 
Biplane method5. Intravenous contrast was not required as all subjects had good endocardial 
definition.  
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Cardiopulmonary exercise testing 
Cardiopulmonary exercise testing was performed in an upright position with a COSMED 
E100w cycle ergometer (Rome, Italy) using a ramp protocol 20-30 W/min to volitional 
exhaustion. Breath-by-breath gas exchange analysis was performed using a dedicated 
COSMED Quark CPEX metabolic cart (Rome, Italy). Peak oxygen consumption (pVO2) was 
calculated in ml/kg/min. 
Cardiovascular magnetic resonance 
Cardiovascular magnetic resonance imaging was performed using methods described and 
analysed using semi-automated software11 . All measurements were recorded as absolute 
values and indexed to body-surface area as per the DuBois-DuBois formula12. Delayed 
enhancement images were acquired after administration of gadolinium diethylenetriamine 
pentaacetate. Isolated late gadolinium enhancement (LGE) at the right ventricular insertion 
was not considered pathological as this is a common finding in healthy endurance athletes8. 
 
Statistical analysis: 
Analyses were performed using SPSS (Version 25.0 IBM Corp). Shapiro-Wilk Test and 
analysis of histograms were performed to assess for normality. Continuous variables are 
presented as mean ± standard deviation or median and interquartile ranges. Comparison of 2 
groups was by unpaired Student’s t-tests or Mann-Whitney-U tests. Comparisons of more 
than two groups were performed by one-way ANOVA (with Bonferroni post-hoc test) or 
Krushal-Wallis (with Dunn’s post hoc test) where appropriate. Categorical variables were 
presented as percentages and were compared using Fisher Exact Tests or Chi Squared Test. 
Receiver operating characteristic (ROC) curve analysis was performed to test the sensitivity 
of the echocardiographic variables in predicting DCM. Athlete was considered a negative 
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test, whereas DCM was considered a positive test.  Optimal cut-off values, defined by the 
best compromise between sensitivity and specificity, were calculated by the Youden’s Index 
using Medcalc 19.0.7. Inter-reader variability was assessed by intra-class correlation 
coefficients. Statistical significance was defined for p-values<0.05. Forward step-wise 
logistic regression was used. Stress echocardiographic variables with an area under the curve 
(AUC) >0.7 as identified by the ROC curve were included in the model. 
To determine sample sizes, we estimated using a previous study of exercise radionuclide 
angiography which showed those with contractile reserve (representing athletes) had an 
increase in LVEF of 5±6% and those with poor outcome (representing DCM) had a change of 
LVEF of 0±5%13. Using these assumptions, we calculated we needed at least 21 in each 
cohort to provide 80% power. To allow for a margin of error we aimed to recruit at least 30 
DCM patients and match them for age and baseline LVEF with the ‘grey-zone’ athletes 
(α=5%, 1-β=80%, n=21). 
 
Ethics: 
Full ethical approval was granted by the Chelsea Research Ethics Committee, London UK 
and participants provided informed written consent. 
 
RESULTS 
Demographics 
Patients with DCM 
The DCM patients were aged 39.5±13.4 (18-68) years. The majority (88.6%) were white. All 
patients were in NYHA Class 1 and exercised for an average of 4(2-8)hours per week. 
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Twenty-four (68.8%) were on beta-blockers and 23 (65.7%) on ACE-inhibitors or 
angiotensin II receptor blockers. Three patients (8.6%) had an implantable cardioverter-
defibrillator in-situ. Fifteen patients (42.9%) had familial DCM, 3 (8.6%) had anthracycline 
induced DCM, 4 (11.4%) had post-viral DCM and 15 (42.9%) had idiopathic DCM.  
 
Athletes 
Athletes with an enlarged LV and baseline LV ejection fraction <55% (‘grey-zone athletes’) 
(32.3± 10.4; range 18-58 years) and control athletes (36.7±7.7; 22-48) were of similar age; 
however ‘grey-zone’ athletes were younger than DCM patients (p=0.035). The majority 
(>90%) were white. ‘Grey-zone’ athletes and control athletes exercised for a mean of 
14.0(10-20) and 10(8.5-14.75)hours per week respectively and participated primarily in 
endurance sports.  ‘Grey-zone’ athletes participated in cycling (n=8), endurance running 
(n=10), triathlon (n=3), rowing (n=3) and rugby (n=1). Control athletes competed in cycling 
(n=15); triathlon (n=2), endurance running (n=6) and rowing (n=1).  
 
Electrocardiography 
All participants were in sinus rhythm. Fourteen (40%) DCM patients had an abnormal ECG 
(some with multiple abnormalities) compared with 2 (8.0%) ‘grey-zone’ athletes and 1 
(4.2%) control athlete (p=0.0007). Among the DCM cohort, 4 had left bundle branch block, 2 
had pathological q waves, 2 had ST-segment depression, 5 had T-wave inversion and 4 had ≥ 
2 ventricular extrasystoles. None of these abnormalities were seen in either athletic cohort.  
Ten (28.6%) DCM patients had an abnormal Holter of which 5 (14.3%) showed > 500 
ventricular extrasystoles, 2 (5.7%) revealed isolated NSVT and 3(8.5%) had both. None of 
the ‘grey-zone’ athletes had an abnormal Holter.   
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NT-proBNP 
There was no significant difference in median NT-proBNP between the 3 groups [50(26-262) 
pg/ml in the DCM group, 33.0 (23.5-57.5)pg/ml in the ‘grey-zone’ and 28(17.5-42)pg/ml in 
the athlete controls (p=0.131)]. Ten (28.6%)  DCM patients had a NT-proBNP>125pg/ml 
(upper limit of normal)14 compared with  none of the athletes.  
 
Baseline Echocardiography 
There were no significant differences in the LV end-diastolic dimensions or ejection fraction 
between ‘grey-zone’ athletes or DCM patients. Both groups had a larger LV cavity compared 
with control athletes but there were no differences between the groups in left atrial indexed 
volume or LV mass. LA dilatation was observed in 12 (48.0%) grey-zone athletes, 16 
(66.7%) control athletes and 12 (34.3%) of DCM patients. Diastolic dysfunction was noted in 
5 DCM patients (2 grade I, 2 grade II and 1 grade III). None of the athletes had diastolic 
dysfunction. Both athletic cohorts showed significantly higher TDI measurements compared 
with DCM patients. Lateral S’ wall was higher in both athletic groups compared to DCM 
patients. All the ‘grey-zone’ athletes and 28 (80.0%) DCM patients had a lateral E’ ≥ 10 
cm/s.  Twenty (80%) ‘grey-zone’ athletes and 15 (42.9%) DCM patients had an S’ wave≥10 
cm/sec.  
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Table 1: Baseline echocardiographic characteristics. 
 DCM (n=35) Healthy  athletes 
with LV dilatation 
and LVEF<55% 
‘grey-zone’(n=25) 
Athlete controls 
(n=24) 
P value 
LAVi (ml/m2) 29.2(24.4-
35.2) 
33.7 (30.0-37.5)  35.6 (31.3-40.7) 0.081 
LVEDD (mm) 60.3±2.2* 59.3±2.3* 53.3±3.3 <0.0001 
LVEDD/BSA 28.6±3.6 29.8±2.0 28.2±2.7 0.137 
LVESD (mm) 45.7±5.5* 41.8±3.4* 35.3±3.7 <0.0001 
LVESD/BSA 21.7±3.6 21.0±2.2 18.7±2.4 <0.0001 
LV Mass (g) 209.8±58.1 200.3±47.9 180.6±30.4 0.081 
Baseline LVEDV (ml) 185.27±31.2* 185.0 ±20.4* 152.4±22.9 <0.0001 
Baseline LVESV (ml) 97.9±22.8* 92.7±12.0* 64.4±11.7 <0.0001 
Baseline SV (ml) 87.3±16.3 92.6±12.0 88.1±13.7 0.346 
LV ejection fraction 
(%) 
47.6±5.4* 49.9±2.5* 58.3±2.3 <0.0001 
TAPSE (mm) 22.2±4.0 23.6±3.2 24.5±4.1 0.059 
RVD1 (mm) 40.2±5.6‡ 45.4 ±4.6 41.4±5.0‡ 0.001 
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RVD2 (mm) 27.6±5.1 31.9. ±5.5 29.5±5.5 0.010 
Mitral E wave (cm/s) 0.71±0.20 0.52±0.15 0.88±0.17 0.487 
Mitral A wave (cm/s) 0.52±0.15 0.44±0.14 0.46±0.10 0.094 
Mitral E/A ratio 1.53±0.62 1.97±0.66 1.93±0.97 0.096 
Lateral E’ (cm/s) 13.7±4.8 17.2±4.4† 17.1±3.3† 0.008 
Lateral S’ (cm/s) 8.8±2.3 11.4±2.3† 11.7±1.9† <0.0001 
Lateral E/E’ 5.99±2.32 4.33±1.35† 4.53±1.03† 0.004 
Average E/E’ 6.75±1.91 5.24±1.61† 5.30±1.26† 0.007 
 
BSA=body surface area; LA=left atrial; LAVi=left atrial volume indexed; LV=left 
ventricular; LVEDD=left ventricular end-diastolic dimension; LVEDV=left ventricular end-
diastolic volume; LVESD=left ventricular end-systolic dimension; LVESV=left ventricular 
end-systolic volume; RVD1=right ventricular basal dimension; RVD2=right ventricular mid-
cavity dimension; RVD3=right ventricular longitudinal dimension 3; SV=stroke volume; 
TAPSE=tricuspid annular plane systolic excursion.*=non-significant between the DCM 
patients and athletes in the ‘grey-zone’; †= non-significant between ‘grey-zone’ and control 
athletes. ‡non-significant between DCM and athlete controls 
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Speckle Tracking Imaging 
Average GLS was highest in athlete controls (-17.4±1.9%), followed by ‘grey-zone’ athletes 
(-16.0±2.1%) and DCM patients (-13.6±3.0%) p<0.0001. A significant proportion of ‘grey-
zone’ athletes (n=17; 68%), 14 (n=14; 58.3%) control athletes and 27 (n=27; 79.4%) DCM 
patients had GLS values outside the normal range (<-17%).5  
 
Exercise echocardiogram 
All cohorts demonstrated improvement in indices of diastolic (E’) and longitudinal systolic 
function (S’) at peak exercise, however the athletes showed a greater improvement in lateral 
S’ compared with DCM patients (Table 2)Change in LV ejection fraction≤11% and peak LV 
ejection fraction≤63% were considered the optimal ‘cut-off’ to distinguish between DCM and 
‘grey-zone’ athletes (Table 3).All but one of the ‘grey-zone’ athletes (96.0%) failed  to 
increaseLV ejection fraction >11% as did 19 (79.2%) control athletes (Figure 1) compared 
with only 8 (22.9%) DCM patients.   All athlete controls and 23 (92.0%) ‘grey-zone’ athletes 
achieved a peak LV ejection fraction>63% compared with only 6 (17.1%) DCM patients 
(Figure 2). Thirty (85.7%) DCM patients failed to increase LV ejection fraction by >11% or 
achieve a peak ejection fraction > 63%. Combining the inability to achieve a peak exercise 
LVEF>63% and a change in LVEF>11% exercise echocardiography had a sensitivity of 
85.7% and specificity of 92.0%.  
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Table 2: Stress echocardiographic characteristics. 
 
 DCM (n=35) Athlete in the  
‘grey-zone’ 
(n=25) 
Athlete 
controls 
(n=24) 
P value 
Total Watts  234.6±48.0 308.6±59.6* 293.5±59.6* <0.0001 
Peak LVEDV (ml) 176.3±40.3† 167.4±17.5† 140.7±22.8 <0.0001 
Peak LVESV (ml) 86.2±34.7† 56.2±11.3† 40.3±4.9 <0.0001 
Peak SV (ml) 90.1±22.8 111.2 ±15.6 101.8±17.9 <0.0001 
Peak LV ejection fraction (%) 52.0.±11.5 67.6 ±3.9* 71.4±3.4* <0.0001 
Change in LV ejection fraction 
(%) 
4.9±8.9 17.7 ±4.1 13.1±3.1 <0.0001 
Peak mitral E wave 1.34±0.28 1.30±0.27 1.46±0.24 0.217 
Peak Lateral E’ (cm/s) 21.5±5.5 23.6±5.2 23.8±5.8 0.266 
Peak Lateral E/E’ 6.6±2.3 5.9±2.0 5.86±1.84 0.463 
Peak S’ (cm/s) 15.6±5.0 22.1±6.1* 22.5±6.6* <0.0001 
Peak SBP (mmHg) 189.5±26.7 210.3±24.7* 202.3±27.2* 0.007 
Peak DBP (mmHg) 98.0 ±11.0 102.3 ±13.9 94.1±14.50 0.018 
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Peak HR (bpm) 148.6±15.4‡ 162.2 ±11.1 150.6±9.7‡ 0.01 
bpm=beats per minute; BP=blood pressure; DBP= diastolic blood pressure; HR=heart rate; 
LV=left ventricular; LVEDV=left ventricular end-diastolic volume; LVESV=left ventricular 
end-systolic volume; SBP=systolic blood pressure; SV=stroke volume. * non-significant 
between ‘grey-zone’ and control athletes.†=non-significant between ‘grey-zone’ and DCM 
‡non-significant between DCM and athlete controls 
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Cardiovascular Magnetic Resonance  
All but 1 DCM patient and 1 athlete with a dilated LV and LVEF >55% (‘grey zone’) 
underwent a CMR. Pathological late gadolinium enhancement was observed in 17 (50.0%) 
DCM patients (mid wall n=12 and subepicardial n=5) compared with none of the ‘grey-zone’ 
athletes (supplementary Table 1).  
Cardiopulmonary exercise testing:  
There were no significant differences in cardiopulmonary parameters between either athletic 
group and both achieved superior results compared to DCM patients (supplementary Table 
2).  A significant proportion (n=25; 71.4%) of DCM patients had a normal pV0215 with 
7(20%) achieving a pV02 of >120% predicted. Of these 7, all had ventricular arrhythmias on 
Holter and 6 had the late enhancement on CMR.   
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Discriminating ability of echocardiographic parameters 
Receiver-operator characteristic curve analysis showed peak LV ejection fraction ≤63% 
(AUC 0.904; p<0.0001) and change LV ejection≤11% (AUC 0.906; p<0.0001) predicted 
DCM with good sensitivity and excellent specificity (Table 3). Step-wise logistic regression 
model including a change in LV ejection fraction ≤ 11%, peak LV ejection fraction ≤ 63%, 
peak stroke volume ≤ 94 ml and peak S’≤ 21 cm/s as predictors of DCM, revealed a that 
change in LV ejection fraction ≤11% independently predicted DCM.  The final model had a 
Nagelkerke R2 of 0.677.  
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Table 3: Receiver operator characteristic curve analysis evaluating biomarkers and 
structural and functional stress echocardiographic parameters to distinguish 
betweendilated cardiomyopathy and athletic adaptation.  
 
Variable Optimal 
‘cut-off’* 
AUC Sensitivity Specificity P value 
NT-proBNP  >75 pg/ml 0.645 48.6% 96.0% 0.045 
E’ Lateral Peak <25cm/s 0.638 78.8% 48.0% 0.066 
S’ Lateral Peak ≤21cm/s 0.792 84.4% 64.0% <0.001 
Stroke Volume Peak  ≤94ml 0.754 62.9% 96.0% <0.001 
LV Ejection Fraction  ≤63% 0.904 82.9% 92.0% <0.0001 
Change in left ventricular 
ejection fraction from 
baseline to peak exercise  
≤11% 0.906 77.1% 96.0% <0.0001 
AUC=area under the curve; LV=left ventricular.*Value calculated by Youden’s Index as best 
compromise between sensitivity and specificity 
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Inter-observer variability 
Agreement between observers for the echocardiographic variables was assessed on a random 
sample of 40 stress echocardiograms using intra-class coefficient between the primary 
observer and an independent observer blinded to the initial readings and other results. The 
intra-class coefficients for the assessment of baseline LV ejection fraction, the difference 
between baseline to peak LV ejection fraction and peak LV ejection fraction were 0.734, 
0.877and 0.899 respectively.  
 
DISCUSSION 
To our knowledge, this is the first study which has comprehensively assessed the utility of a 
cascade of investigations to differentiate between the athletes with an enlarged LV and LV 
ejection fraction<55% (‘grey zone’) and morphologically mild DCM. Our results reveal the 
combination of investigations including NT-proBNP, electrocardiogram, Holter and CMR 
will fail to diagnose DCM>30% of cases. Whereas NT-proBNP>125 pg/ml was highly 
specific for DCM, most affected active patients had normal values. The electrocardiogram 
has a sensitivity of 9016% and 80%17 in hypertrophic and arrhythmogenic cardiomyopathy 
respectively; however only 40% of our active individuals with DCM demonstrated abnormal 
electrocardiograms7. Although, beyond the scope of this paper, genetic testing may have a 
role in resolving this diagnostic conundrum, however it is limited by the relatively high cost 
and low yield for results. 
 
Indices of diastolic and longitudinal function. 
Baseline echocardiographic markers of systolic and diastolic function as assessed by E’ and 
S’ at the lateral mitral annulus had a sensitivity of 51.4% and 88.6% respectively in 
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differentiating between ‘grey-zone’ athletes and DCM patients. Although GLS was higher in 
the ‘grey-zone’ athletes compared to DCM patients, over 50% had low values5. Interpretation 
of these results is challenging because currently there is no clear consensus on ‘normal’ GLS 
values athletes with a borderline or low LV ejection fraction. A meta-analysis by Beaumont 
et al18, reported that GLS values in athletes ranged from -16.5 to-23.3% and were lower in 
endurance athletes. Our results suggest that GLS may be of limited value in this context as 
low values may not be pathological. Further research is required on the spectrum of GLS 
values in endurance athletes with borderline or mildly depressed LV function at rest.  
 
Exercise stress echocardiography 
Our results demonstrate the importance of exercise echocardiography in differentiating 
between these entities. Failure to increase LV ejection fraction by>11% from baseline to peak 
exercise is a useful marker of impaired contractile reserve. Only 6 patients with DCM were 
able to generate a LV ejection fraction >63% at peak exercise compared to more than 90% of 
the ‘grey-zone’ athletes and all of the athletic controls and therefore the inability to achieve a 
peak LVEF>63% is an additional marker of pathology. The sensitivity of either of these 
parameters was around 80% and the specificity around 90%. Combining these parameters to 
define a ‘normal’ test reduces the false negatives to 5(14.2%) with only 2 (8%) false positive 
results.  
 
There is limited data used to define contractile reserve in health and this has predominantly 
focused on pharmacological and non-echocardiographic methods13,19,20 .  We used exercise 
echocardiography as it is more physiological and exercise echocardiography is readily 
available to the physician. Our findings are in-keeping recent study using exercise CMR 
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which also found that a failure to increase LV ejection fraction by >11% at peak exercise 
predicted DCM21. 
Cardiopulmonary exercise testing 
Although all but one of the ‘grey-zone’ athletes showed normal pV02, we observed normal 
pV02 in three quarters of the DCM cohort. Additionally, superior pV02 >120% predicted was 
seen in a fifth of our cohort which is similar to a published study looking athletes with 
hypertrophic cardiomyopathy22. All of the individuals with a pV02>120% predicted had 
ventricular arrhythmias and most had late enhancement on CMR. Therefore, highly trained 
individuals may have excellent functional capacity despite significant pathology 
 
Cardiovascular Magnetic Resonance 
 In our study, CMR identified pathological LGE in only 50% patients with DCM, suggesting 
that baseline CMR at rest is not enough on its own to exclude pathology which gives further 
importance to the role of stress echocardiography in this setting. Although we did not utilise 
T1 and T2 mapping techniques, data suggests  these techniques may be useful in 
distinguishing athlete’s heart from DCM23. 
 
Algorithm 
Based on our findings, we have produced a clinical algorithm with diagnostic thresholds to 
aid physicians when assessing highly active individuals with a dilated LV and a LV ejection 
fraction <55% (Figure 3) and demonstrated its utility using our data (Figure 4). The 2 
individuals without CMR have been excluded from analysis. The combination of NT-
proBNP, ECG and Holter monitoring would confirm DCM in <60% of cases. An additional 
exercise echocardiogram, would result in a diagnosis in 31 (91.2%) cases. A subsequent 
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CMR could exclude pathology in another 3% of cases without impact on false positives. The 
algorithm has a sensitivity of 94.1%, specificity of 83.3%, positive predictive value of 88.9% 
and negative predictive value of 90.9%. More than 70% of our DCM patients had a normal 
pV02 therefore we would not recommend this investigation in isolation. 
 
Limitations 
Study participants were predominantly white and exclusively male therefore results may not 
readily be applicable to female athletes or the black athletic population. Given the rarity of 
patients with DCM who are asymptomatic and athletes in the ‘grey-zone’, the numbers 
studied are relatively small. The algorithm was derived and assessed in the same cohort 
which may result in over optimistic results, therefore larger studies are required to validate 
our findings. Due to the cross-sectional nature of the study we are unable to confidently 
exclude the development DCM in the ‘grey-zone’ athletes in the future.  
CONCLUSION 
When attempting to differentiate between physiological LV enlargement with a 
borderline/low baseline LV ejection fraction from mild DCM, a combination of NT-proBNP, 
electrocardiogram, Holter monitoring, baseline echocardiographic and CMR parameters have 
a modest discriminating value; however exercise echocardiography has good sensitivity and 
excellent specificity.  
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Figure titles and legends: 
 
Figure 1: 
(a) Change in LV ejection fraction from baseline to peak exercise in the healthy athletes 
with LV dilatation and LVEF<55% (the ‘grey-zone’) (left), athlete controls (centre) and 
individuals with morphologically mild DCM (right). Each circle represents an individual 
and the horizontal line represents the mean and the 95% confidence intervals. Almost all the 
athletes in both cohorts increase the LV ejection fraction by >11% compared to the DCM 
cohort who demonstrate a heterogenous response. DCM=dilated cardiomyopathy; LVEF=left 
ventricular ejection fraction. 
 
(b) The change in ejection fraction from baseline to peak exercise. The healthy athletes 
with LV dilatation and LVEF<55% (‘grey-zone)’ are on the left, the DCM cohort on the right 
and the control athletes in the centre. All the athletes demonstrate an increase in LV ejection 
fraction compared to the DCM patients who show a heterogenous response.  
DCM=dilated cardiomyopathy; LVEF=left ventricular ejection fraction. 
 
 
Figure 2: Peak exercise LV ejection fraction. This figure shows peak exercise LV ejection 
fraction from baseline to peak exercise in the healthy athletes with LV dilatation and 
LVEF<55% (‘grey-zone’) (left), control athletes (centre) and DCM cohort (right). Each circle 
represents an individual and the horizontal line represents the mean and the 95% confidence 
intervals. All the athlete controls and almost all the ‘grey-zone’ athletes increase their LV 
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ejection fraction to >63% from baseline to peak exercise which is in contrast to the DCM 
cohort. DCM=dilated cardiomyopathy; LVEF=left ventricular ejection fraction 
Figure 3:  
This figure outlines a simple algorithm to aid physicians when assessing active individuals 
with LV dilatation and LVEF <55%. On the left are the changes that would support 
physiological adaptation and on the right those that suggest pathological remodelling. The 
electrocardiogram was interpreted as per the international recommendations in athletes7. 
CMR=cardiovascular magnetic resonance; DCM=dilated cardiomyopathy; LV=left 
ventricular; LVEF=left ventricular ejection fraction; LBBB=left bundle branch block; 
LGE=late gadolinium enhancement; NSVT=non-sustained ventricular tachycardia; TWI=T-
wave inversions; VEs=ventricular extrasystoles 
 
Figure 4: 
The figure demonstrates the utility of the step-wise clinical algorithm for differentiating 
between physiological adaptation and morphologically mild DCM in apparently healthy 
individuals with LV dilatation and LVEF<55%.  The number and percentages of both cohorts 
with abnormal investigations is shown with the cumulative true negative and true positive 
results on the extreme right and left respectively. The overall sensitivity of the algorithm is 
94.1% with a specificity of 83.3%. The positive predictive value is 90.3% with a negative 
predictive value of 94.7%. 
CMR=cardiovascular magnetic resonance; DCM=dilated cardiomyopathy; 
ECG=electrocardiogram; LV=left ventricular; LVEF=left ventricular ejection fraction; 
NPV=negative predictive value; NT-proBNP=N-terminal pro-brain natriuretic peptide; 
PPV=positive predictive value; TN=true negatives; TP=true positives 
